Dopamine receptors in a rat model of minimal brain dysfunction. 1982

J Eisenberg, and E Brecher-Fride, and R Weizman, and R P Ebstein, and R H Belmaker

A model of minimal brain dysfunction (MBD) in rats based on injection of 6-OH-dopamine (DA) intracisternally on the 5th day of life has been described previously. Since 6-OH-DA pretreatment has been reported in adult rats to lead to a compensatory rise in DA receptor number, we measured DA receptor number in animals treated with 6-OH-DA on the 5th day of life, after completion of behavioral observations on days 17, 20 and 23 of life. Rats pretreated with 6-OH-DA at day 5 were found, on sacrifice on day 23, to have a mean increase of about 20% in caudate spiperone binding. There was a significant correlation between spiperone binding and gross activity in 6-OH-DA-treated animals but not in untreated animals. Since the significant correlation between receptor number and gross activity is negative and DA receptor stimulators are known to increase activity, it appears that receptor number changes are not directly related to hyperactivity.

UI MeSH Term Description Entries
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D002421 Caudate Nucleus Elongated gray mass of the neostriatum located adjacent to the lateral ventricle of the brain. Caudatus,Nucleus Caudatus,Caudatus, Nucleus,Nucleus, Caudate
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006892 Hydroxydopamines Dopamines with a hydroxy group substituted in one or more positions. Hydroxydopamine
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000831 Animals, Newborn Refers to animals in the period of time just after birth. Animals, Neonatal,Animal, Neonatal,Animal, Newborn,Neonatal Animal,Neonatal Animals,Newborn Animal,Newborn Animals
D001289 Attention Deficit Disorder with Hyperactivity A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V) ADHD,Attention Deficit Disorder,Attention Deficit Hyperactivity Disorder,Brain Dysfunction, Minimal,Hyperkinetic Syndrome,Minimal Brain Dysfunction,ADDH,Attention Deficit Disorders with Hyperactivity,Attention Deficit Hyperactivity Disorders,Attention Deficit-Hyperactivity Disorder,Attention Deficit Disorders,Attention Deficit-Hyperactivity Disorders,Deficit Disorder, Attention,Deficit Disorders, Attention,Deficit-Hyperactivity Disorder, Attention,Deficit-Hyperactivity Disorders, Attention,Disorder, Attention Deficit,Disorder, Attention Deficit-Hyperactivity,Disorders, Attention Deficit,Disorders, Attention Deficit-Hyperactivity,Dysfunction, Minimal Brain,Syndromes, Hyperkinetic
D013134 Spiperone A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA. Spiroperidol,Spiroperone

Related Publications

J Eisenberg, and E Brecher-Fride, and R Weizman, and R P Ebstein, and R H Belmaker
October 1976, Science (New York, N.Y.),
J Eisenberg, and E Brecher-Fride, and R Weizman, and R P Ebstein, and R H Belmaker
October 1976, Science (New York, N.Y.),
J Eisenberg, and E Brecher-Fride, and R Weizman, and R P Ebstein, and R H Belmaker
October 1976, Science (New York, N.Y.),
J Eisenberg, and E Brecher-Fride, and R Weizman, and R P Ebstein, and R H Belmaker
January 1976, Science (New York, N.Y.),
J Eisenberg, and E Brecher-Fride, and R Weizman, and R P Ebstein, and R H Belmaker
February 1980, Psychopharmacology,
J Eisenberg, and E Brecher-Fride, and R Weizman, and R P Ebstein, and R H Belmaker
February 1973, Annals of the New York Academy of Sciences,
J Eisenberg, and E Brecher-Fride, and R Weizman, and R P Ebstein, and R H Belmaker
April 1976, Diseases of the nervous system,
J Eisenberg, and E Brecher-Fride, and R Weizman, and R P Ebstein, and R H Belmaker
June 1979, Brain research,
J Eisenberg, and E Brecher-Fride, and R Weizman, and R P Ebstein, and R H Belmaker
January 1979, Communications in psychopharmacology,
J Eisenberg, and E Brecher-Fride, and R Weizman, and R P Ebstein, and R H Belmaker
September 1973, Fortschritte der Medizin,
Copied contents to your clipboard!